Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29378921 | 1.00 | KDM1A (0.50) | KDM1ADPP4GRIN2BMAPTCA1 | |
| Hydrochloric Acid SCHEMBL29711570 | 0.98 | KDM1A (0.49) | KDM1ADPP4GRIN2BMAPTCA1 | |
| Hydrochloric Acid SCHEMBL4869944 | 0.98 | KDM1A (0.49) | KDM1ADPP4GRIN2BMAPTCA1 | |
| SCHEMBL12656430 | 0.89 | GRIN2B (0.56) | DPP4GRIN2BCA1CA2MTNR1A | |
| SCHEMBL255286 | 0.83 | GRIN2B (0.53) | DPP4GRIN2BMAPTMTNR1AMTNR1B | |
| SCHEMBL29434614 | 0.83 | GRIN2B (0.53) | DPP4GRIN2BMAPTMTNR1AMTNR1B | |
| SCHEMBL13846495 | 0.82 | GRIN2B (0.55) | DPP4GRIN2BMAPTCA1CA2 | |
| SCHEMBL13981017 | 0.81 | MTNR1A (0.51) | DPP4GRIN2BMAPTMTNR1AMTNR1B | |
| Bicarbonate SCHEMBL2441660 | 0.81 | GRIN2B (0.51) | DPP4GRIN2BMAPTMTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL10493696 | 0.81 | GRIN2B (0.51) | DPP4GRIN2BMAPTMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019178267-A2 | INDUCTIVE REGENERATION OF THE AIRWAY BY TRANSCRIPTIONAL FACTOR MODULATION OF GLANDULAR MYOEPITHELIAL STEM CELLS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2019-09-19 | — | — | WO | claimed |
| CN-102143961-B | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON INC | 2014-11-05 | — | — | CN | claimed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | claimed |
| JP-2011526251-A | — | — | 2011-10-06 | — | — | JP | claimed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | claimed |
| EP-2310386-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2011-04-20 | — | — | EP | claimed |
| EP-1883451-B9 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2011-02-09 | — | — | EP | claimed |
| CN-101910157-A | Indole compounds and methods of treating visceral pain | NEURAXON INC | 2010-12-08 | — | — | CN | claimed |
| EP-1883451-B1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2010-11-24 | — | — | EP | claimed |
| EP-2220074-A1 | 3,5-SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | Neuraxon, INC. (CA) | 2010-08-25 | — | — | EP | claimed |
| CN-101247853-A | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC (CA) | 2008-08-20 | — | — | CN | claimed |
| EP-1909781-A1 | THERAPEUTIC COMBINATION COMPRISING A NMDA RECEPTORS BLOCKER AND A NARCOTIC ANALGESIC SUBSTANCE | CHIESI FARMACEUTICI S.p.A. (IT) | 2008-04-16 | — | — | EP | claimed |
| EP-1888568-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS WITH DUAL NOS INHIBITORY ACTIVITY AND MUOPIOID AGONIST ACTIVITY | Neuraxon Inc. (CA) | 2008-02-20 | — | — | EP | claimed |
| EP-1883451-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2008-02-06 | — | — | EP | claimed |
| WO-2007063418-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2007-06-07 | — | — | WO | claimed |
| WO-2007017058-A1 | THERAPEUTIC COMBINATION COMPRISING A NMDA RECEPTORS BLOCKER AND A NARCOTIC ANALGESIC SUBSTANCE | CHIESI FARMACEUTICI S.P.A. (IT) | 2007-02-15 | — | — | WO | claimed |
| WO-2007017764-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS WITH DUAL NOS INHIBITORY ACTIVITY AND MUOPIOID AGONIST ACTIVITY | NEURAXON, INC. (CA) | 2007-02-15 | — | — | WO | claimed |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-16 | — | — | US | claimed |
| WO-2004039371-A2 | COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF NEUROPATHIC PAIN | PHARMACIA CORPORATION (US) | 2004-05-13 | — | — | WO | claimed |
| US-20040082543-A1 | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain | PHARMACIA CORPORATION | 2004-04-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | KDM1A 1705/4885DPP4 2163/4885GRIN2B 108/4885 |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NOS2, NOS1, NOS3 | KDM1A 1705/4885DPP4 2163/4885GRIN2B 108/4885 |
| US-20040082543-A1 | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain | GRIN2A, GRIN2B, GRIN3A | KDM1A 1088/4885DPP4 3152/4885GRIN2B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.